Adverum Biotechnologies Inc expected to post a loss of $2.25 a share - Earnings Preview

Adverum Biotechnologies

08/08/2025 14:55

Adverum Biotechnologies Inc ADVM.OQ ADVM.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Adverum Biotechnologies Inc is for a loss of $2.25 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Adverum Biotechnologies Inc is $21.00, about 88.3% above its last closing price of $2.45

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.91
-1.81
-2.25
Missed
-24
Dec. 31 2025
-1.36
-1.96
Missed
-44.2
Sep. 30 2024
-1.29
-1.31
-1.30
Beat
0.5​
Jun. 30 2024
-1.44
-1.47
-0.89
Beat
39.4
​​Mar. 31 2024
-1.55
-1.40
-1.50
Missed
-6.8
Dec. 31 2023
-3.35
-3.37
-2.30
Beat
31.7​
Sep. 30 2023
-3.06
-3.15
-3.30
Missed
-4.7
Jun. 30 2023
-3.12
-3.29
-3.10
Beat
5.7

This summary was machine generated August 8 at 13:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)